Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 10, 2023

CNS Relapse Incidence and Survival Outcomes in Patients With High-Risk DLBCL Receiving High-Dose Methotrexate CNS Prophylaxis

American Journal of Hematology


Additional Info

Disclosure statements are available on the authors' profiles:

American Journal of Hematology
Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis
Am. J. Hematol 2023 May 10;[EPub Ahead of Print], R Bennett, A Ruskova, C Coomarasamy, E Theakston, L Berkahn, S Jackson, M Christophers, S Wong, S Issa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.

Further Reading